A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
Didemnin B (NSC #335319) was administered i.v. to 26 evaluable patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix at 6.3 mg/m(2) every 28 days until progression of disease. No patient had had prior cytotoxic therapy alone. Some patients (4) were exposed to radiation sensitizers. There was one complete responder (4.5%). Six patients had stable disease (27.3%) and 15 (68.2%) had increasing disease. The toxicities were significant, with 11 patients (42.3%) experiencing grade 3 or 4 adverse effects. Didemnin B, when used with this dose and schedule, has minimal activity in squamous cell carcinoma of the cervix.
Malfetano
J H
JH
Department of Obstetrics and Gynecology, Albany Medical Center Hospital, Buffalo, New York, USA.
Blessing
J A
JA
Homesley
H D
HD
Look
K Y
KY
McGehee
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D047630:Depsipeptides; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D012074:Remission Induction; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000932:Antiemetics; D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; D011838:Radiation-Sensitizing Agents; C030051:didemnins